HIV Drug Market by Medication class [multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase stand transfer inhibitors] - Global Opportunity Analysis and Industry Forecast, 2014-2022 Update Available On-Demand
|
LI_171867
|
Pages: 163
|
Feb
2017 |
10407 Views
|
|
|
|
Author(s) :
Shubhangi Bawkar and Archana Kamble
|
Tables: 26
|
Charts: 42
|
Formats*:
|
|
HIV Drug Market Overview
Global HIV Drug Market was valued at $20,448 million in 2015 and is expected to garner $26,458 million by 2022, registering a CAGR of 3.7% during the forecast period 2016-2022. Human immunodeficiency virus (HIV) is one of the most infectious diseases with around 36.7 million people suffering by the end of 2015, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS).
Â
The major factors that boost the HIV drug market growth include increase in prevalence of HIV and rise in treatment & diagnosis rate. Moreover, there is an increase in the government initiative to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments in the control of HIV virus growth. Thus, rise in awareness through such government initiatives are also expected to drive the HIV drugs market. However, stringent government regulations for the approval and commercialization of HIV drugs is expected to restrain the industry growth.
Hiv Drug Market: Segmentation
Get more information on this report : Request Sample Pages
Segment Review:
The global HIV drugs market is segmented by medication class and geography. On the basis of medication class, the industry is classified into multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase stand transfer inhibitors. Among the medication class, the multi-class combination drugs hold the largest market share as it’s the most advanced technique used for the treatment of HIV infection. This is due to the increase in adoption of drugs from this medication class owing to their better results in the control of HIV & related coinfections and their ease in consumption & adherence.
Top Investment Pockets
Get more information on this report : Request Sample Pages
Top Impacting Factors:
Increase in Number of HIV Infected Patients Worldwide
According to WHO, 36.7 million people were diagnosed with HIV/AIDS in 2015, whereas, 1.1 million people died of AIDS-related illness in the same year. The world has very high prevalence of people living with HIV owing to the various factors, such as lack of availability of medication for the treatment of HIV infection. In the emerging nations including sub-Saharan Africa, countries with low income do not have sufficient funds to buy high price drugs leading to increase in the population living with HIV.
Initiatives Taken By Various Government Associations To Raise Awareness About Diagnosis and Management of HIV/AIDS
The federal government agencies, and various associations across the globe have introduced many initiatives and education campaigns for community awareness to address HIV prevention, treatment, and care. For instance, the U.S. government launched the National HIV/AIDS Strategy, a five year initiative with various strategic goals, in 2010. These include the plan to reduce incidence of HIV infections and to increase the access to treatment. This National HIV/AIDS Strategy was further extended by the government to 2020 in July 2015.
The increase in awareness among people regarding diagnosis and management of the diseases due to various initiatives increase the treatment rate and thus, this factor acts as an important driver for the growth of the HIV drug market.
Introduction of Generic Drugs of HIV Drugs
Generic drugs are the revised copy of the branded drugs with slight modifications in the ingredients and are launched in the market after the patent expiry of the branded drugs. Companies, such as Mylan Pharmaceuticals Inc., Hetero Labs Ltd., and other such companies majorly work on generic version of the HIV drugs, launching them at cheaper costs. Patent expiration of the blockbuster drugs helps introduce the generic version, which promotes generic drug pharmaceutical market growth. The adoption of generic HIV drugs is very high because they offer same treatment as branded drugs at a very lost cost and are highly preferred in low income regions, such as Africa.
Stringent Regulatory Requirements for the Approval and Commercialization of HIV Drugs
Each new HIV drug must go through the regulatory approval process and meet the standard requirements. This process is stringent and time-consuming. The commercialization and approval of these drugs is regulated by agencies, such as CE and FDA. The manufacturer must compile a file for every pipeline drug to include information, such as AIP (Application Integrity Policy), its use, and risk assessment while filling the drug for approval. It is also involved in drug manufacturing and development to establish licensing. Similarly, EMA protects public and animal health by ensuring safety of HIV drugs for human. These stringent regulatory standards and guidelines obstruct the entrance of new players in the market.
Increase in Number of Products in the Pipeline
Various pharma giants, such as Boehringer Ingelheim, Gilead Sciences, Inc., Merck & Co., Inc. GSK, Roche, and others are continuously involved in the drug development to offer better drugs for the treatment of HIV for complete cure and to provide products with very less or no side effects. These companies also utilize various innovative technologies, such as cell therapy and immunomodulation along with antivirals for the drug development. For instance, Bictegravir/F/TAF, F/TAF, GS-9620, which undergo clinical trials. This results in emergence of more effective treatments, showing quick results to treat HIV/AIDS. The launch of such innovative drugs in the market is expected to create the opportunities for HIV drugs market in the future.
Geographic Analysis:
The North American region accounted half of the share in the overall HIV drug market in 2015, and is expected to maintain this lead throughout the forecast period. The growth in the North American HIV drug market is attributed to well-established healthcare system, higher diagnosis & treatment rate, government funding for R&D, and increase in the adoption of advanced treatment options from HIV infected population. However, Asia-Pacific & LAMEA are projected to grow at a faster CAGR during the forecast period.
Hiv Drug Market Key Benefits:
- The study provides an in-depth analysis of the HIV drugs market, with current trends and future estimations to elucidate the imminent investment pockets.
- It presents a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.
- Extensive analysis of the HIV drug market, by medication class, assists in the effective treatment of HIV/AIDS.
- Key players are profiled and their strategies are analyzed thoroughly, which predicts the competitive outlook of the market.
Hiv Drug Market Key Segments:
By Medication Class
- Multi-Class Combination Drugs
- Atripla
- Complera
- Prezcobix/Prezista
- Stribild
- Triumeq
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Combivir
- Emtriva
- Epivir
- Epzicom
- Trizivir
- Truvada
- Viread
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Edurant
- Intelence
- Rescriptor
- Sustiva
- Viramune (Immediate Release)
- Protease Inhibitors (PIs)
- Aptivus
- Crixivan
- Kaletra
- Lexiva
- Norvir
- Reyataz
- Viracept
- Fusion Inhibitors (FI)
- Fuzeon
- Entry Inhibitors
- Selzentry
- HIV Integrase Stand Transfer Inhibitors.
- Isentress
- Tivicay
By Geography
- North America
- Europe
- Asia-Pacific
- LAMEA
The Key Players
- Boehringer Ingelheim International GmbH
- Merck & Co., Inc.
- ViiV Healthcare
- AbbVie
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb
- Gilead Sciences, Inc.
- Johnson & Johnson
- Cipla Limited
List of Other Players
- (These players are not profiled in the report. The same will be included on request)
- Daiichi Sankyo
- Emcure
- Hetero Drugs
- Mylan
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS
3.4. PRODUCT PIPELINE ANALYSIS
3.5. MARKET DYNAMICS
CHAPTER 4 HIV DRUGS MARKET, BY MEDICATION CLASS
4.1. OVERVIEW
4.2. MULTI-CLASS COMBINATION DRUGS
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Atripla: market size and forecast
4.2.5. Complera: market size and forecast
4.2.6. Prezista: market size and forecast
4.2.7. Stribild: market size and forecast
4.2.8. Triumeq: market size and forecast
4.3. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS)
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Combivir: market size and forecast
4.3.5. Emtriva: market size and forecast
4.3.6. Epivir: market size and forecast
4.3.7. Epzicom: market size and forecast
4.3.8. Trizivir: market size and forecast
4.3.9. Truvada: market size and forecast
4.3.10. Viread: market size and forecast
4.4. NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Edurant: market size and forecast
4.4.5. Rescriptor: market size and forecast
4.4.6. Sustiva: market size and forecast
4.4.7. Viramune: market size and forecast
4.5. PROTEASE INHIBITORS (PIS)
4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast
4.5.4. Aptivus: market size and forecast
4.5.5. Crixivan: market size and forecast
4.5.6. Kaletra: market size and forecast
4.5.7. Lexiva: market size and forecast
4.5.8. Norvir: market size and forecast
4.5.9. Reyataz: market size and forecast
4.5.10. Viracept: market size and forecast
4.6. FUSION INHIBITORS
4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast
4.6.4. Fuzeon: market size and forecast
4.7. ENTRY INHIBITORS - CCR5 CO-RECEPTOR ANTAGONIST
4.7.1. Key market trends
4.7.2. Key growth factors and opportunities
4.7.3. Market size and forecast
4.7.4. Selzentry: market size and forecast
4.8. HIV INTEGRASE STRAND TRANSFER INHIBITORS
4.8.1. Key market trends
4.8.2. Key growth factors and opportunities
4.8.3. Market size and forecast
4.8.4. Isentress: market size and forecast
4.8.5. Tivicay: market size and forecast
CHAPTER 5 HIV DRUGS MARKET, BY GEOGRAPHY
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. NORTH AMERICA
5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
5.3. EUROPE
5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
5.4. ASIA-PACIFIC
5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
5.5. LAMEA
5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
CHAPTER 6 COMPANY PROFILES
6.1. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
6.1.1. Overview
6.1.2. Operating business segments
6.1.3. Business performance
6.1.4. Key strategic moves & developments
6.2. MERCK & CO., INC.
6.2.1. Overview
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves & developments
6.3. BRISTOL-MYERS SQUIBB
6.3.1. Overview
6.3.2. Operating business segments
6.3.3. Business performance
6.3.4. Key strategic moves & developments
6.4. GILEAD SCIENCES, INC.
6.4.1. Overview
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves & developments
6.5. VIIV HEALTHCARE
6.5.1. Overview
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves & developments
6.6. JOHNSON & JOHNSON
6.6.1. Overview
6.6.2. Operating business segments
6.6.3. Business performance
6.6.4. Key Strategic Moves & Developments
6.7. F. HOFFMANN-LA ROCHE LTD
6.7.1. Overview
6.7.2. Operating business segments
6.7.3. Business performance
6.7.4. Key Strategic Moves & Developments
6.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.
6.8.1. Overview
6.8.2. Operating business segments
6.8.3. Business performance
6.8.4. Key Strategic Moves & Developments
6.9. ABBVIE
6.9.1. Overview
6.9.2. Operating business segments
6.9.3. Business performance
6.9.4. Key strategic moves & developments
6.10. CIPLA
6.10.1. Overview
6.10.2. Operating business segments
6.10.3. Business performance
6.10.4. Key Strategic Moves & Developments
LIST OF OTHER PLAYERS IN THE VALUE CHAIN
(These players are not profiled in the report. The same will be included on request)
- Daiichi Sankyo
- Emcure
- Hetero Drugs
- Mylan
- AstraZeneca
LIST OF TABLES
TABLE 1. HIV PRODUCT PIPELINE: ANTIVIRALS
TABLE 2. HIV PRODUCT PIPELINE: CELL THERAPY/GENE THERAPY
TABLE 3. HIV PRODUCT PIPELINE: IMMUNOMODULATORS
TABLE 4. GLOBAL HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 5. GLOBAL MULTI-CLASS COMBINATION DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 6. GLOBAL MULTI-CLASS COMBINATION DRUGS MARKET, BY BRAND, 2014-2022 ($MILLION)
TABLE 7. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 8. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET, BY BRAND TYPE, 2014-2022 ($MILLION)
TABLE 9. GLOBAL NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 10. GLOBAL NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) MARKET, BY BRAND TYPE, 2014-2022 ($MILLION)
TABLE 11. GLOBAL PROTEASE INHIBITORS (PIS) MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12. GLOBAL PROTEASE INHIBITORS (PIS) MARKET, BY BRAND TYPE, 2014-2022 ($MILLION)
TABLE 13. GLOBAL FUSION INHIBITORS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 14. GLOBAL ENTRY INHIBITORS - CCR5 CO-RECEPTOR ANTAGONIST MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 15. GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 16. GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS MARKET, BY BRAND TYPE, 2014-2022 ($MILLION)
TABLE 17. GLOBAL HIV DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 18. NORTH AMERICA: HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 19. EUROPE: HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 20. AISA-PACIFIC: HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 21. LAMEA: HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 22. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
TABLE 23. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 24. MERCK: COMPANY SNAPSHOT
TABLE 25. MERCK: OPERATING SEGMENTS
TABLE 26. BMS: COMPANY SNAPSHOT
TABLE 27. GILEAD: COMPANY SNAPSHOT
TABLE 28. VIIV HEALTHCARE: COMPANY SNAPSHOT
TABLE 29. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 30. JOHNSON & JOHNSON: OPERATING BUSINESS SEGMENTS
TABLE 31. ROCHE: COMPANY SNAPSHOT
TABLE 32. ROCHE: OPERATING SEGMENTS
TABLE 33. TEVA PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 34. TEVA: OPERATING SEGMENTS
TABLE 35. ABBVIE: COMPANY SNAPSHOT
TABLE 36. CIPLA LIMITED: COMPANY SNAPSHOT
LIST OF FIGURES
FIGURE 1. HIV DRUGS: MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 2014-2016
FIGURE 4. HIV DRUGS MARKET SHARE ANALYSIS, 2015
FIGURE 5. PRODUCT PIPELINE ANALYSIS
FIGURE 6. GLOBAL ATRIPLA MARKET, 2014-2022 ($MILLION)
FIGURE 7. GLOBAL COMPLERA MARKET, 2014-2022 ($MILLION)
FIGURE 8. GLOBAL PREZISTA MARKET, 2014-2022 ($MILLION)
FIGURE 9. GLOBAL STRIBILD MARKET, 2014-2022 ($MILLION)
FIGURE 10. GLOBAL TRIUMEQ MARKET, 2014-2022 ($MILLION)
FIGURE 11. GLOBAL COMBIVIR MARKET, 2014-2022 ($MILLION)
FIGURE 12. GLOBAL EMTRIVA MARKET, 2014-2022 ($MILLION)
FIGURE 13. GLOBAL EPIVIR MARKET, 2014-2022 ($MILLION)
FIGURE 14. GLOBAL EPZICOM MARKET, 2014-2022 ($MILLION)
FIGURE 15. GLOBAL TRIZIVIR MARKET, 2014-2022 ($MILLION)
FIGURE 16. GLOBAL TRUVADA MARKET, 2014-2022 ($MILLION)
FIGURE 17. GLOBAL VIREAD MARKET, 2014-2022 ($MILLION)
FIGURE 18. GLOBAL EDURANT MARKET, 2014-2022 ($MILLION)
FIGURE 19. GLOBAL INTELENCE MARKET, 2014-2022 ($MILLION)
FIGURE 20. GLOBAL RESCRIPTOR MARKET, 2014-2022 ($MILLION)
FIGURE 21. GLOBAL SUSTIVA MARKET, 2014-2022 ($MILLION)
FIGURE 22. GLOBAL VIRAMUNE MARKET, 2014-2022 ($MILLION)
FIGURE 23. GLOBAL APTIVUS MARKET, 2014-2022 ($MILLION)
FIGURE 24. GLOBAL CRIXIVAN MARKET, 2014-2022 ($MILLION)
FIGURE 25. GLOBAL KALETRA MARKET, 2014-2022 ($MILLION)
FIGURE 26. GLOBAL LEXIVA MARKET, 2014-2022 ($MILLION)
FIGURE 27. GLOBAL NORVIR MARKET, 2014-2022 ($MILLION)
FIGURE 28. GLOBAL REYATAZ MARKET, 2014-2022 ($MILLION)
FIGURE 29. GLOBAL VIRACEPT MARKET, 2014-2022 ($MILLION)
FIGURE 30. GLOBAL FUZEON MARKET, 2014-2022 ($MILLION)
FIGURE 31. GLOBAL SELZENTRY MARKET, 2014-2022 ($MILLION)
FIGURE 32. GLOBAL ISENTRESS MARKET, 2014-2022 ($MILLION)
FIGURE 33. GLOBAL TIVICAY MARKET, 2014-2022 ($MILLION)
FIGURE 34. BOEHRINGER INGELHEIM: REVENUE, 2013-2015 ($MILLION)
FIGURE 35. MERCK: REVENUE, 2013-2015 ($MILLION)
FIGURE 36. BMS: REVENUE, 2013-2015 ($MILLION)
FIGURE 37. GILEAD: REVENUE, 2013-2015 ($MILLION)
FIGURE 38. JOHNSON & JOHNSON: REVENUE, 2013-2015, ($MILLION)
FIGURE 39. ROCHE: REVENUE, 2013-2015, ($MILLION)
FIGURE 40. TEVA: REVENUE, 2013-2015, ($MILLION)
FIGURE 41. ABBVIE: REVENUE, 2013-2015 ($MILLION)
FIGURE 42. CIPLA: REVENUE, 2013-2015 ($MILLION)
Human immunodeficiency virus (HIV) attacks the body’s immune system, leading to complete damage of this system, making the host system susceptible to infection. The virus attacks the CD4 cells, whose primary role is to help the immune system defend infections, thus destroying the first-line defense of the human body and exposing the person for various infections. HIV is one of the most alarming and widespread disease. The major route of transmission of HIV infection is through unprotected sex, use of contaminated needle, breast milk of the HIV infected mother, and infected blood.
Human immunodeficiency virus (HIV) had affected around 36.7 million globally by the end of 2015, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS). Antiretroviral Therapy (ART) drugs are used for the treatment of HIV.
Combination of drugs has emerged as an effective solution for the treatment of HIV infection, which largely contributes to the growth of this market. These drugs contain the combination two or more drugs/active ingredients in a single tablet for effective treatment of the HIV infection. The patient prescribed on combination drugs has to take only one tablet per day and hence increase the patient’s treatment compliance rate due to more convenience at a lesser price, as a single tablet is used for cure of the infection instead of taking multiple tablets.
Geographically, North America and Europe market hold larger share in the HIV drugs market due to high HIV infected population, well-established healthcare systems in these regions leading to higher diagnosis & treatment rate, and the presence of top pharmaceutical companies in the region. The Asia-Pacific market offers lucrative growth opportunity due to increase in demand for advanced health care services in the emerging economies (such as India and China) and increase in prevalence of HIV infected population coupled with rise in government initiatives to control the spread of HIV in these nations. Thus, the emerging markets have a huge potential for the market growth in the HIV drug market.
Download Sample
Purchase Full Report of
HIV Drug Market- Global Opportunity Analysis and Industry Forecast, 2014-2022
- Online Only
- $3565
- Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
- $3961
- Restricted to one authorized user
- One print only
- Available in Excel
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
- $5540
- Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
- $6654
- Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF - $9280
- Unlimited within company/enterprise
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Buy Full Version
"HIV Drug Market"
Purchase Enquiry